Thomas B Karasic
Overview
Explore the profile of Thomas B Karasic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amit U, Shagun M, Plastaras J, Metz J, Karasic T, Lubas M, et al.
Radiat Oncol
. 2024 Aug;
19(1):102.
PMID: 39090660
Background: Biliary tract cancers (BTC) are rare and aggressive malignancies originating from intrahepatic and extrahepatic bile ducts and the gallbladder. Surgery is the only curative option, but due to late-stage...
2.
Brown T, Gimotty P, Mamtani R, Karasic T, Yang Y
JCO Clin Cancer Inform
. 2024 Aug;
8:e2300220.
PMID: 39088775
Purpose: Systemic therapy with atezolizumab and bevacizumab can extend life for patients with advanced hepatocellular carcinoma (HCC). However, there is substantial variability in response to therapy and overall survival. Although...
3.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle J, Morizane C, Karasic T, et al.
Future Oncol
. 2024 Jun;
20(36):2811-2822.
PMID: 38884254
What Is This Summary About?: This summary describes the results from a phase 2 study called FOENIXCCA2. The study evaluated treatment with futibatinib in people with a rare form of...
4.
Yarchoan M, Powderly J, Bastos B, Karasic T, Crysler O, Munster P, et al.
Cancer Res Commun
. 2024 Mar;
4(4):1100-1110.
PMID: 38551394
Purpose: TPST-1120 is a first-in-class oral inhibitor of peroxisome proliferator-activated receptor α (PPARα), a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation, angiogenesis, and inflammation,...
5.
Bi J, Witt E, McGovern M, Cafi A, Rosenstock L, Pearson A, et al.
Adv Sci (Weinh)
. 2023 Dec;
11(9):e2308346.
PMID: 38084435
Modulation of autophagy, specifically its inhibition, stands to transform the capacity to effectively treat a broad range of cancers. However, the clinical efficacy of autophagy inhibitors has been inconsistent. To...
6.
Brown T, Yablonovitch A, Till J, Yen J, Kiedrowski L, Hood R, et al.
Clin Cancer Res
. 2023 Jul;
29(24):5207-5216.
PMID: 37486343
Purpose: PARP inhibitors (PARPi) provide an effective maintenance option for patients with BRCA- or PALB2-mutated pancreatic cancer. However, mechanisms of PARPi resistance and optimal post-PARPi therapeutic strategies are poorly characterized....
7.
Karasic T, Eads J, Goyal L
JCO Precis Oncol
. 2023 Apr;
7:e2200573.
PMID: 37053534
No abstract available.
8.
Brown T, Mamtani R, Gimotty P, Karasic T, Yang Y
J Cancer Res Clin Oncol
. 2023 Mar;
149(6):2345-2354.
PMID: 36862158
Purpose: Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. Combination atezolizumab and bevacizumab has improved the outcomes for patients with advanced disease. We sought to determine...
9.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle J, Morizane C, Karasic T, et al.
N Engl J Med
. 2023 Jan;
388(3):228-239.
PMID: 36652354
Background: Alterations in fibroblast growth factor receptor 2 () have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding...
10.
Joaquim M, Furth E, Fan Y, Song H, Pickup S, Cao J, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36011011
KPC (KrasG12D:Trp53R172H:Pdx1-Cre) and CKS (KrasG12D:Smad4L/L:Ptf1a-Cre) mice are genetically engineered mouse (GEM) models that capture features of human pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasms (IPMN), respectively. We compared...